

# MAYZENT<sup>®</sup>▼

0.25 mg, 1 mg and 2 mg film-coated tablets (siponimod)

## Physician's Checklist

Important points to remember before, during and after treatment with Mayzent<sup>®</sup>



▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: [www.hpra.ie](http://www.hpra.ie). Adverse events could also be reported to Novartis preferably via [www.report.novartis.com](http://www.report.novartis.com) or by email: [drugsafety.dublin@novartis.com](mailto:drugsafety.dublin@novartis.com) or by calling 01 2080 612.

HPRA date of approval: Date TBC

 **NOVARTIS**







